达雷妥尤单抗注射液是一种靶向ADP-核糖基环化酶(CD38)的重组全人源IgG1单克隆抗体，为原研药兆 珂的生物类似药，按照治疗用生物制品3.3类申报，适用于治疗多发性骨髓瘤成年患者。该产品研发遵 循生物类似药相关研究指导原则，药学及非临床研究结果显示，该产品与原研参照药在质量、安全性和 有效性方面高度相似，支持开展后续临床研究。 新诺威（300765）(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(以下简 称"巨石生物")于近日收到国家药品监督管理局核准签发的关于达雷妥尤单抗注射液的《药物临床试验 批准通知书》，将于近期开展临床试验。 ...

Core Viewpoint - The announcement indicates that the company’s subsidiary, Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Daratumumab injection, a biosimilar to the original drug, targeting multiple myeloma patients [1] Group 1 - The clinical trial approval is for Daratumumab injection, a recombinant fully human IgG1 monoclonal antibody targeting ADP-ribosyl cyclase (CD38) [1] - The product is classified as a biosimilar to the original drug, known as Zhaoke®, and is submitted under the category of biological products for therapeutic use [1] - The research results indicate that the biosimilar shows high similarity in quality, safety, and efficacy compared to the reference drug, supporting the initiation of subsequent clinical studies [1]

Core Viewpoint - The company XinNuoWei (300765.SZ) announced that its subsidiary, JuShi Bio, has received approval from the National Medical Products Administration for the clinical trial of Daratumumab injection, a biosimilar to the original drug, which is intended for the treatment of adult patients with multiple myeloma [1] Group 1 - The clinical trial approval notification allows the company to proceed with clinical trials for the drug [1] - Daratumumab is a biosimilar of the original drug, known as Zhaoke® [1] - The drug is specifically aimed at treating adult patients diagnosed with multiple myeloma [1] Group 2 - Following the approval, the drug must undergo clinical trials and receive further approval from regulatory authorities before it can be marketed and sold [1] - There are inherent risks associated with the clinical trial process, including the possibility of trial results not meeting expectations, failure to obtain necessary approvals, delays in market entry, or lower-than-expected sales post-launch [1]

Core Viewpoint - The announcement indicates that the subsidiary of XinNuoWei, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Daratumumab injection, a biosimilar to the original drug, which is intended for the treatment of adult patients with multiple myeloma [1] Group 1 - The clinical trial approval notification for Daratumumab injection has been issued, allowing the company to commence clinical trials shortly [1] - Daratumumab injection is a recombinant fully human IgG1 monoclonal antibody targeting ADP-ribosylation factor (CD38) [1] - The drug is a biosimilar to the original drug, Zhaoke®, which is used for treating multiple myeloma [1]

人民财讯12月23日电，新诺威（300765）12月23日公告，控股子公司石药集团巨石生物制药有限公司近 日收到国家药监局核准签发的关于达雷妥尤单抗注射液的《药物临床试验批准通知书》，将于近期开展 临床试验。该药品适用于治疗多发性骨髓瘤成年患者。 ...

石药创新制药股份有限公司 证券代码：300765 证券简称：新诺威 公告编号：2025-101 关于控股子公司达雷妥尤单抗注射液 三、药物的其他相关情况 达雷妥尤单抗注射液是一种靶向 ADP-核糖基环化酶（CD38）的重组全人源 IgG1 单克隆抗体，为原研药兆珂®的生物类似药，按照治疗用生物制品 3.3 类申 报，适用于治疗多发性骨髓瘤成年患者。该产品研发遵循生物类似药相关研究指 1 剂 型：注射剂 注册分类：治疗用生物制品 3.3 类 申请事项：临床试验 受 理 号：CXSL2500876 申请人：石药集团巨石生物制药有限公司 获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 石药创新制药股份有限公司（以下简称"公司"）的控股子公司石药集团巨石 生物制药有限公司（以下简称"巨石生物"）于近日收到国家药品监督管理局核 准签发的关于达雷妥尤单抗注射液的《药物临床试验批准通知书》，将于近期开 展临床试验。现将相关情况公告如下： 二、药物的基本信息 药物名称：达雷妥尤单抗注射液 审批结论：根据《中华人民共和国药品管理法》及 ...

Group 1 - The core viewpoint of the articles indicates a positive outlook for the Chinese stock market, with predictions of significant growth driven by factors such as investor sentiment and economic recovery [2][3]. - The ChiNext ETF Tianhong (159977) has shown notable performance, with a trading volume of 1.05 billion yuan and a weekly growth of 2.57 billion yuan, reflecting strong investor interest in high-growth opportunities within the A-share market [1]. - Goldman Sachs forecasts a potential 38% increase in the Chinese stock market by the end of 2027, attributing this to a shift from expectation-driven to profit-driven market dynamics [2]. Group 2 - Institutional perspectives suggest that a classic "cross-year-spring" market trend is beginning, supported by increased investments from major institutional investors and anticipated acceleration in central budget investments [3]. - The ChiNext ETF Tianhong (159977) is highlighted as a key product for investors looking to capitalize on the recovery of high-growth sectors in the A-share market [1][3]. - Various ETFs are available for investment, including those focused on technology, healthcare, and renewable energy, indicating a diverse range of options for investors [4].

Policy Developments - The National Healthcare Security Administration announced that the long-term care insurance system will transition from pilot programs to full establishment during the 14th Five-Year Plan period, aiming to cover nearly 300 million people and benefit over 3.3 million disabled individuals, with total fund expenditures exceeding 100 billion yuan [2] Drug and Device Approvals - Novo Nordisk's weight-loss version of semaglutide injection has been approved in China for cardiovascular indications, aimed at reducing the risk of major cardiovascular adverse events in adults with a BMI of 27 or higher who have been diagnosed with cardiovascular disease. The drug can achieve over a 20% weight reduction in about one-third of patients and reduce the risk of major adverse cardiovascular events by 20% [4] - GlaxoSmithKline announced that its new drug, Meplazumab injection, has been approved in China for the maintenance treatment of adults with chronic obstructive pulmonary disease (COPD) characterized by elevated eosinophils [5] Capital Market Activities - Weisi Medical plans to sell part of its fixed assets for a total price of 119 million yuan, which is expected to impact the company's net profit attributable to shareholders by approximately 10 million yuan in 2026 [8] - AstraZeneca and JAKS Pharmaceuticals have reached a global exclusive licensing agreement for the pan-KRAS inhibitor JAB-23E73, with JAKS receiving an upfront payment of 100 million USD and potential milestone payments of up to 1.915 billion USD [9] Industry Events - XinNuoWei announced the resignation of board member Cai Lei due to work changes, who will focus on his role at Shiyao Group, which is aligned with the group's strategy of "innovation + internationalization" [11] - Sanli Pharmaceutical signed a technology transfer contract with Hainan University for the HXW2324 compound and related patents, with a total transfer price of 200 million yuan, aimed at developing new treatments for Alzheimer's disease [12] - A new vaccine strategy developed by the Scripps Research Institute aims to prevent fatal filovirus infections by using engineered self-assembling protein nanoparticles to display viral surface proteins, enhancing immune response [13]

证券日报网讯 12月22日，新诺威发布公告称，公司第六届董事会第二十九次会议审议通过《关于与关 联方共同投资设立合资公司暨关联交易的议案》。 （文章来源：证券日报） ...

Core Viewpoint - Recently, Shiyao Group (01093HK) has made significant announcements, including its subsidiary XinNuoWei (300765) submitting an IPO application to the Hong Kong Stock Exchange and the appointment of Cai Lei as CEO, indicating a strategic shift towards innovation and R&D investment during a challenging performance period [1][2] Group 1: Management Changes - Cai Lei, the son of the chairman Cai Dongchen, has been appointed as CEO, which is seen as a positive signal for the company's transformation strategy due to his familiarity with the company [1][3] - The management restructuring is part of a broader transition from a generic drug giant to an innovation-driven pharmaceutical company, with a focus on R&D and international expansion [2][5] Group 2: R&D Investment - Shiyao Group has significantly increased its R&D investment, reaching 5.7 billion yuan in 2024, maintaining double-digit growth for several years [5] - The company has 15 clinical-stage drugs in development, with 9 being ADC drugs, and has secured over $1.2 billion in international collaborations [4][6] Group 3: Financial Performance - For the first three quarters, Shiyao Group reported revenues of 19.891 billion yuan, a year-on-year decrease of 12.32%, and a net profit of 3.511 billion yuan, down 7.06%, primarily due to drug procurement and price adjustments [8] - Despite the revenue decline, R&D expenses reached 4.185 billion yuan, a year-on-year increase of 7.9%, accounting for 27.1% of the revenue from the core pharmaceutical business [8] Group 4: Strategic Initiatives - The company is focusing on business integration and resource synergy, particularly with the restructuring of ST Jingfeng (Jingfeng Pharmaceutical), where it invested 526 million yuan to gain control [7] - The integration aims to leverage Jingfeng's capabilities in cardiovascular, orthopedic, and anti-tumor plant drugs to enhance market share and product upgrades [7]